Literature DB >> 3867353

Determination of gemfibrozil in plasma by high performance liquid chromatography.

H Hengy, E U Kölle.   

Abstract

A sensitive and specific method for the determination of 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid (gemfibrozil, Gevilon) at therapeutic concentrations in plasma is described. The method is based on high performance liquid chromatography and the use of ibuprofen as internal standard. Gemfibrozil and the internal standard are extracted from acidified plasma into cyclohexane and the resulting residue is analyzed on a commercial reversed phase column with acetonitrile/water 1:1 and 0.2% phosphoric acid as mobile phase. The eluted peaks are detected by UV-absorption at 225 nm. The sensitivity is approx. 50 ng/ml plasma using a 0.5-ml sample. The applicability to pharmacokinetic studies of gemfibrozil is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3867353

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

1.  Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study.

Authors:  Joseph E Rower; Lane R Bushman; Kyle P Hammond; Rajendra S Kadam; Christina L Aquilante
Journal:  Biomed Chromatogr       Date:  2010-12       Impact factor: 1.902

2.  Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.

Authors:  Mikko Niemi; Aleksi Tornio; Marja K Pasanen; Hanna Fredrikson; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

3.  Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.

Authors:  Mikko Niemi; Janne T Backman; Laura Juntti-Patinen; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

4.  The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.

Authors:  Aleksi Tornio; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2006-07-11       Impact factor: 2.953

5.  Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.

Authors:  Jari J Lilja; Janne T Backman; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

6.  Gemfibrozil absorption and elimination in kidney and liver disease.

Authors:  H Knauf; E U Kölle; E Mutschler
Journal:  Klin Wochenschr       Date:  1990-07-05

Review 7.  Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.

Authors:  P A Todd; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

8.  Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.

Authors:  Aleksi Tornio; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2007-02-27       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.